[{"id":"2b60a198-36bb-4737-9740-9e0001718260","acronym":"","url":"https://clinicaltrials.gov/study/NCT01758328","created_at":"2021-01-18T07:43:30.186Z","updated_at":"2024-07-02T16:35:24.465Z","phase":"Phase 1","brief_title":"Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT01758328","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • busulfan • ATA520"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-05"},{"id":"a82c37b0-b7de-4909-9ed6-4017ba0331ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00620633","created_at":"2021-01-18T02:18:25.353Z","updated_at":"2024-07-02T16:36:33.932Z","phase":"Phase 1","brief_title":"Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation","source_id_and_acronym":"NCT00620633","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1","pipe":" | ","alterations":" WT1 overexpression","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATA520"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2008","start_date":" 02/08/2008","primary_txt":" Primary completion: 02/26/2021","primary_completion_date":" 02/26/2021","study_txt":" Completion: 02/26/2021","study_completion_date":" 02/26/2021","last_update_posted":"2021-03-02"}]